Guerbet: positive opinion from the CHMP for Elucirem
The European Commission is expected to issue its decision by the end of 2023.
In September 2022, Elucirem was approved by the US Food and Drug Administration.
As a reminder, Elucirem (Gadopiclenol) is a contrast agent indicated for use in adults and children aged 2 and over for magnetic resonance imaging (MRI).
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction